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SUMMARY
One histologic subtype of ovarian carcinoma, ovarian endometrioid adenocarcinoma (OEA), fre-
quently harbors mutations that constitutively activate Wnt/b-catenin-dependent signaling. We now
show that defects in the PI3K/Pten and Wnt/b-catenin signaling pathways often occur together in
a subset of human OEAs, suggesting their cooperation during OEA pathogenesis. Deregulation of
these two pathways in the murine ovarian surface epithelium by conditional inactivation of the
Pten and Apc tumor suppressor genes results in the formation of adenocarcinomas morphologically
similar to humanOEAswith 100%penetrance, short latency, and rapid progression tometastatic dis-
ease in upwards of 75% of mice. The biological behavior and gene expression patterns of the murine
cancers resemble those of human OEAs with defects in the Wnt/b-catenin and PI3K/Pten pathways.INTRODUCTION
The vast majority of primary ovarian cancers are carcino-
mas, since they show epithelial differentiation. It is widely
believed that ovarian carcinomas usually arise from the
ovarian surface epithelium (OSE) or from surface epithelial
inclusion glands and cysts. Endometriosis is also consid-
ered a plausible and well-documented, but not necessar-ily obligate, precursor of ovarian carcinomas, particularly
those with clear cell or endometrioid differentiation
(Campbell and Thomas, 2001; Bell, 2005). Pathologists
currently employ a classification system for ovarian carci-
nomas based entirely on light microscopic analysis of tu-
mor cell morphology (Scully et al., 1998). At least some of
the morphological heterogeneity of ovarian carcinomas
may be due to aberrant expression of HOX genes, whichSIGNIFICANCE
Ovarian carcinomas can be subclassified into four major types (serous, endometrioid, clear cell, and mucinous)
based on their morphological features. Here, we demonstrate that mutations of the Wnt/b-catenin and PI3K/
Pten signaling pathways cooperate in the development of ovarian endometrioid adenocarcinomas in women
and in mice. Our mouse model of ovarian cancer, based on conditional deletion of Apc and Pten, shows morpho-
logical features, biological behavior, and gene expression profiles similar to human cancers with the same signal-
ing pathway defects. Thismodel should help advance understanding of the pathogenesis of human ovarian cancer
and will likely prove useful for preclinical testing of therapies targeting the Wnt/b-catenin and PI3K/Pten signaling
pathways.Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc. 321
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Mouse Model of Ovarian Endometrioid Adenocarcinomaregulate Mu¨llerian duct differentiation and specify mor-
phological identity within the female reproductive tract
(Cheng et al., 2005). The present clinical management of
a given ovarian cancer is not significantly influenced by
its morphological subtype (serous, endometrioid, clear
cell, ormucinous) (Guppyet al., 2005), thougha substantial
body ofmolecular data indicate that the different subtypes
are generally characterized by distinct genetic alterations
(Bell, 2005). For example, about 85% of mucinous ovarian
adenocarcinomas harbor K-RAS gene mutations, while
K-RAS mutations are much less frequently observed in
clear cell, endometrioid, and typical (high-grade) serous
carcinomas (Ichikawa et al., 1994; Cuatrecasas et al., 1997;
Enomoto et al., 1991). Likewise, mutations of theCTNNB1
gene (encoding b-catenin) are observed in 16%–38% of
ovarian endometrioid adenocarcinomas (OEAs) but are
uncommon in the other types of ovarian carcinomas
(Gamallo et al., 1999; Sagae et al., 1999; Wright et al.,
1999; Wu et al., 2001; Kildal et al., 2005; Catasus et al.,
2004). As in other cancers, the genes mutated in ovarian
cancer typically encode proteins that function in con-
served signaling pathways (Vogelstein and Kinzler, 2004).
A better understanding of how the pathway defects coop-
erate in a given tumor should allow molecularly targeted
therapies to be developed and implemented in the future.
Genetically engineered mouse (GEM) models of each
major subtype of ovarian cancer will undoubtedly prove
useful for improving knowledge of ovarian cancer biology
and for preclinical testing of signal transduction inhibitors
as therapeutics. Historically, most animal models of ovar-
ian cancer were based on xenografting human ovarian
cancer cells into immunodeficient mice. Such models
have limitations, including incomplete recapitulation of
tumor-host interactions and inability to replicate early
stages of tumor development. Recently described GEM
models of ovarian cancer address some limitations of
the xenograft models. Most of the GEMmodels described
thus far result in tumors most closely resembling human
ovarian serous carcinomas (Flesken-Nikitin et al., 2003;
Orsulic et al., 2002; Connolly et al., 2003). Another GEM
model, involving conditional deletion of Pten and activa-
tion of an oncogenic K-ras allele in the ovarian surface ep-
ithelium, results in tumors with apparent morphological
similarity to human OEAs (Dinulescu et al., 2005). How-
ever, K-RAS mutations have been reported in less than
10% of human OEAs (Sieben et al., 2004; Amemiya
et al., 2004; Caduff et al., 1998; Enomoto et al., 1991),
and data supporting cooperation between K-Ras muta-
tion and Pten inactivation in human OEAs are lacking.
Here, we report that activation of PI3K/Pten signaling on
the basis of PTEN inactivation and/or PIK3CA mutation is
significantly associated with canonical Wnt (Wnt/b-cate-
nin/Tcf, hereafter referred to as Wnt/b-cat) signaling path-
way defects in a subset of human OEAs. The OEAs with
deregulated Wnt/b-cat and/or PI3K/Pten signaling tended
to be low grade, and unlike high-grade OEAs, uncom-
monly had p53 mutations. This distinction is a major
source of gene expression variation in OEAs. Notably,
K-RAS mutations were not observed in tumors with Pten322 Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc.inactivation. Deregulation of PI3K/Pten andWnt/b-cat sig-
naling in the murine ovarian surface epithelium was
achieved by conditional deletion of the Pten and Apc
tumor suppressor genes, respectively, and resulted in
tumors with similar morphology, biological behavior, and
gene expression patterns to human OEAs with the same
signaling pathway defects. This model of ovarian cancer
should allow further study of ovarian cancer biology in
an in vivo setting and will likely prove useful for preclinical
testing of Wnt/b-cat and PI3K/Pten signal transduction
inhibitors.
RESULTS
Mutations of PTEN Are Frequently Observed
in Human OEAs with Mutant b-Catenin,
but Not in OEAs with Mutant K-Ras
Previous studies have shown the canonical Wnt (i.e., Wnt/
b-catenin/Tcf) signaling pathway is deregulated in 16%–
38% of human OEAs (Wright et al., 1999; Sagae et al.,
1999; Moreno-Bueno et al., 2001). In our series of 72
primary OEAs, 18 had missense mutations of CTNNB1,
and 1 was found to harbor inactivating mutations in both
alleles of theAPC tumor suppressor gene. Hence, in keep-
ing with published data from others, 26% of our primary
OEAs have mutations predicted to deregulate Wnt/b-cat
signaling. Based on immunohistochemical staining of tu-
mor tissue (data not shown), nuclear accumulation of
b-catenin protein was observed, as expected, in a com-
parable percentage of OEAs (21 of 72) and included 18
samples with CTNNB1 or APC mutations (see Table S1
in the Supplemental Data available with this article online).
b-catenin mutation and immunohistochemistry data from
a subset of these OEAs have been reported earlier (Wu
et al., 2001; Zhai et al., 2002).
Inactivating mutations of the tumor suppressor gene
PTEN have been reported in 14%–21% of OEAs but are
rare in the other types of ovarian carcinomas (Obata
et al., 1998; Catasus et al., 2004). Inactivation of Pten,
the lipid phosphatase that converts PIP3 to PIP2, is one
mechanism by which activation of phosphotidylinositol
3-kinase (PI3K) signaling occurs in human tumors (re-
viewed by Altomare and Testa, 2005). In order to deter-
mine whether defects of the Wnt/b-cat and PI3K/Pten
signaling pathways co-occur in OEA pathogenesis, we
sequenced all nine PTEN exons in our collection of 72 pri-
mary OEAs previously characterized for mutations of Wnt/
b-cat pathway genes. Nonsense, frameshift, or missense
PTEN mutations were identified in 8 of the 72 tumors
(Table 1). Several lines of evidence support the functional
significance of the four missense PTEN mutations we
identified. First, amino acid changes at the same position
of each missense mutation have been reported (http://
www.sanger.ac.uk/genetics/CGP/cosmic/), and one of
these, R130G, affects the codon most frequently mutated
in human cancers. Moreover, all four missense mutations
are in exon 5, which encodes the phosphatase domain of
the Pten protein, and there are several reports in the pub-
lished literature showing the functional significance of
Cancer Cell
Mouse Model of Ovarian Endometrioid AdenocarcinomaTable 1. Mutational Analysis of PTEN and Corresponding Mutations of CTNNB1 and K-RAS in OEAs
Tumor PTEN Mutation CTNNB1 Mutation K-RAS Mutation
ID (Exons 1–9) (Exon 3) (Codons 12 and 13)
OE-13T del T, exon 4, frameshift TCT/TGT none
OE-19T GAG/TAG, exon 1, nonsense TCT/TAT none
OE-31T TAT/AAT, exon 5 (Tyr/Asn) none none
OE-48T ACT/CCT, exon 5 (Thr/Pro) GGA/GAA none
OE-54T ACG/AGG, exon 5 (Thr/Arg) GAC/GCC none
OE-55T del ACTT, exon 8, frameshift TCT/TTT none
OE-63T CAG/TAG, exon 6, nonsense none none
OE-75T GAT/GGT, exon 5 (Gly/Asp) none nonesuch missense mutations, including loss or reduction of
phosphatase activity and increased phosphorylation of
Akt (Han et al., 2000; Kato et al., 2000). Comparable to
other tumor types with activation of the PI3K signaling
pathway due to PTEN inactivation (Thomas et al., 2004;
Baeza et al., 2003), OEAs with mutant PTEN showed
marked reduction or loss of Pten protein and increased
expression of pS6, an indicator of PI3K pathway activa-
tion, based on immunohistochemical staining of tumor tis-
sue (data not shown). Notably, five of the eight OEAs with
mutant PTEN also harbored mutations of CTNNB1. Over-
all, 5 of 19 (26%) primary OEAs with deregulated Wnt/b-
cat signaling also had mutations of PTEN. In contrast,
only 3 of 53 (6%) primary OEAs lacking Wnt/b-cat signal-
ing pathway defects hadPTENmutations. The association
of PTEN mutations with Wnt/b-cat pathway defects in
OEAs is statistically significant (p = 0.026, two-sided
Fisher’s exact test). All 72 OEAs were also evaluated for
the presence ofK-RASmutations at codons 12 and 13. Al-
though K-RAS mutations were identified in 5 of the 72
OEAs (7%; all in codon 12), none of the OEAs with PTEN
mutation harbored a K-RAS mutation. Only 1 of 19 OEAs
with Wnt/b-cat pathway defects had mutant K-RAS. The
low frequency of K-RAS mutations in our series of OEAs
is in accord with several studies in the published literature,
which report K-RAS mutations in less than 10% of OEAs
(Caduff et al., 1998; Enomoto et al., 1991; Sieben et al.,
2004; Amemiya et al., 2004).
PIK3CA, which Encodes the p100a Catalytic Subunit
of PI3K, Is Mutated in a Subset of OEAs
Recently, Oda and colleagues reported a high frequency
of concomitant mutations of PIK3CA and PTEN in uterineendometrioid adenocarcinomas (UEAs) (Oda et al., 2005).
Their mutational analysis of PIK3CA was restricted to
exons 9 and 20 becausemost previously reportedPIK3CA
mutations in other tumor types are clustered in these re-
gions (Samuels et al., 2004). Functional studies suggested
that mutation of both PIK3CA and PTEN may have an
additive effect on PI3K pathway activation. Given the find-
ings in UEAs, we sequenced exons 9 and 20 in our 72 pri-
mary OEAs. We identified five OEAs with PIK3CA muta-
tions (Table 2), a somewhat lower frequency (7%) than
previously reported by Campbell and colleagues, who
identified PIK3CA mutations in 20% of ovarian endome-
trioid and clear cell carcinomas but in only 6% of ovarian
carcinomas when all types were considered (Campbell
et al., 2004). Notably, however, all five OEAs with PIK3CA
mutations also harbored mutations in PTEN (n = 2),
CTNNB1 (n = 2), or both (n = 1). Overall, of the ten OEAs
with PI3K/Pten pathway defects (i.e., PTEN and/or
PIK3CAmutations), seven (70%) also hadWnt/b-cat path-
way defects, whereas of the remaining 62 OEAs se-
quenced for both PIK3CA and PTEN that showed no mu-
tations, only 12 (19%) had Wnt/bcat pathway defects (p =
0.002, two-sided Fisher’s exact test). Taken together, our
findings imply that Wnt/b-cat and PI3K/Pten signaling
pathway defects often cooperate in human OEA patho-
genesis, while defects in K-Ras and the PI3K/Pten path-
way do not. This is not necessarily the case in UEAs, which
have a higher prevalence of both K-RASmutations (13%–
26%) (Caduff et al., 1998) and PTEN mutations (37%–
61%) (Tashiro et al., 1997; Risinger et al., 1998). Indeed,
concurrent K-RAS and PTEN mutations were recently re-
ported in 3 of 24 complex endometrial hyperplasias, pre-
cursors of UEAs (Brachtel et al., 2005). In keeping withTable 2. Mutational Analysis of PIK3CA and Corresponding Mutations of PTEN and CTNNB1 in OEAs
Tumor ID PIK3CA Mutation PTEN Mutation CTNNB1 Mutation
OE-21T H1047R, exon 20 none GGA/GAA (Gly34Glu)
OE-31T H1047R, exon 20 TAT/AAT, exon 5 (Tyr/Asn) none
OE-55T E542K, exon 9 del ACTT, exon 8, frameshift TCT/TTT (Ser37Phe)
OE-71T E542K, exon 9 none GGA/GAA (Gly34Glu)
OE-75T H1047R, exon 20 GAT/GGT, exon 5 (Gly/Asp) noneCancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc. 323
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Mouse Model of Ovarian Endometrioid AdenocarcinomaFigure 1. Gene Expression Profiling of Human Ovarian Carcinomas
(A) Principal component analysis of 99 ovarian carcinomas using all probe sets on the U133A array; the first two principal components are shown.
Individual tumors are annotated with histological type as indicated (OC, clear cell; OE, endometrioid; OM, mucinous; OS, serous).
(B) Same scatter plot showing only the locations of OEAs, annotated with mutational status of CTNNB1, APC, PTEN, PIK3CA, and p53 as
indicated.other data in the published literature, our OEAs with muta-
tions predicted to deregulate theWnt/b-cat and PI3K/Pten
pathways tended to be low-grade, low-stage tumors. Of
44 stage 1 and 2 tumors, 21 had mutations of CTNNB1,
APC, PTEN, and/or PIK3CA, while only 1 of 28 higher-
stage tumors had suchmutations (p = 53 105). Similarly,
14 of 18 grade 1 tumors versus 7 of 54 higher-grade
tumors had PTEN, PIK3CA, APC, and/or CTNNB1 muta-
tions (p = 7 3 107). Clinical and molecular data associ-
ated with the group of 72 OEAs are provided as Supple-
mental Data (Table S1).
p53 Mutations Are Uncommon in OEAs
with Wnt/b-Catenin or PI3K/Pten Pathway
Defects but Are Common in High-Grade OEAs
Previous studies have reported p53 mutations in upwards
of 60% of OEAs, particularly in high-grade tumors (Kolasa
et al., 2006).We sequenced TP53 exons 5–8 in all 72 OEAs
and performed immunohistochemical staining for p53
protein in all but three samples. p53mutations were docu-
mented in 32 of 72 OEAs (Table S1); five additional OEAs
showed diffuse and strong nuclear accumulation of p53
protein, presumably because of a missense mutation out-
side of the exons sequenced. Of the 18 grade 1OEAs, only
3 had documented or presumptive p53 mutations. In con-
trast, p53 mutations were identified in 34 of 54 higher-
grade (2 or 3) tumors (p = 0.0009, two-sided Fisher’s exact
test). Moreover, we found documented or presumptive
p53 mutations in only 2 of 22 OEAs with Wnt/b-cat and/
or PI3K/Pten signaling defects, but p53 mutations were
present in 35 of 50 OEAs lacking defects in these path-
ways (p = 1.5 3 106). Our findings support the division
of OEAs into two subgroups. One group of OEAs is char-
acterized by mutations that deregulate the canonical Wnt/
b-cat and PI3K/Pten signaling pathways. These tumors
typically lack p53 mutations and are low grade (grade 1),324 Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc.whereas a second group of OEAs harbor mutations of
p53 without Wnt/b-cat or PI3K/Pten deregulation and
tend to be high grade (grade 2 or 3).
We previously used Affymetrix HuGeneFL (7069 probe
sets) oligonucleotide microarrays to profile gene expres-
sion in 104 primary ovarian carcinomas including all four
major histological types (Schwartz et al., 2002). We
showed that mucinous and clear cell carcinomas were
readily distinguishable from serous carcinomas based
on their gene expression profile. In contrast, OEAs
showed substantial overlap with the other types. We
have performed a similar gene expression analysis of 99
primary ovarian carcinomas (see Table S2 for details; 37
endometrioid, 41 serous, 13 mucinous, and 8 clear cell
carcinomas, including 71 from the earlier study) using
higher-density (22,283 probe sets) U133A arrays. Princi-
pal component analysis of log-transformed data was em-
ployed to provide a visual depiction of the variation in gene
expression among the 99 human tumors (Figure 1A). Prin-
cipal components were computed utilizing all probe sets
on the arrays. Even in this unsupervised analysis, the se-
rous, clear cell, andmucinous carcinomas are largely sep-
arable from each other. In contrast, the OEAs are rather
dispersed, with several overlapping the region occupied
by serous carcinoma samples, and a few close to clear
cell andmucinous carcinoma samples.When the gene ex-
pression data for the OEAs are annotated with the muta-
tional status of p53 and the Wnt/b-cat and PI3K/Pten sig-
naling pathways (Figure 1B), it becomes evident that
OEAs with p53 mutations are those with greatest overlap
to the serous carcinomas and are largely distinct from
OEAs with Wnt/b-cat and/or PI3K/Pten signaling pathway
defects. Notably, p53mutations have been reported in up-
wards of 60% of serous carcinomas, but in only 16% and
10% of mucinous and clear cell carcinomas, respectively
(Schuijer and Berns, 2003).
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Mouse Model of Ovarian Endometrioid AdenocarcinomaFigure 2. Ovarian Bursal Injection of AdCre Results in Ovarian Surface Epithelial Expression of Cre Recombinase
(A) Schematic diagram of ovarian bursal AdCre injection strategy (modified from Nagy et al., 2003).
(B)Whole-organ stainingofb-galactosidase in themouseoviduct andovary followingAdCre injection (left) compared to control uninjectedovary (right).
(C) Photomicrograph showing histochemical detection of LacZ in the ovarian surface epithelium. Note the absence of staining in the underlying
gonadal stromal and follicular cells.Deregulation of the Wnt/b-Catenin and PI3K/Pten
Signaling Pathways in the Murine Ovarian Surface
Epithelium Induces Tumors with Similar Biological
Behavior and Morphology to Human OEAs
In light of our data identifying co-occurrence of Wnt/b-cat
and PI3K/Pten signaling defects in human ovarian endo-
metrioid tumorigenesis, we wished to determine whether
deregulation of these two pathways in the murine ovarian
surface epithelium (MOSE) induces endometrioid-like
ovarian tumors in mice. In order to achieve this, we em-
ployed the method described by Flesken-Nikitin et al.
and Dinulescu et al. to inactivate the Pten and Apc tumor
suppressor genes in the MOSE (Flesken-Nikitin et al.,
2003; Dinulescu et al., 2005). Replication-deficient adeno-
virus expressing Cre recombinase (AdCre) was first in-
jected into the ovarian bursa (Figure 2A) ofGt(ROSA)26Sor
reporter mice to verify delivery of the adenovirus to the
MOSE. As expected, after staining for b-galactosidase
activity using standard protocols, visual inspection of the
ovary revealed blue staining (Figure 2B), which was local-
ized to the MOSE in frozen sections (Figure 2C). We ob-
tained the PtenloxP/loxP transgenic mice developed by
T.Mak and colleagues (University Health Network, Univer-
sity of Toronto) in which Cre-mediated recombination
results in deletion of Pten exons 4 and 5 (Suzuki et al.,
2001). We also obtained the ApcloxP/loxP transgenic mice
developed by T. Noda and colleagues (The Cancer Insti-
tute, Tokyo, Japan) (Shibata et al., 1997). In these animals,
Cre-mediated recombination deletes a region of Apc en-
compassing exon 14 and induces a frameshift mutation
at codon 580. The PtenloxP/loxP and ApcloxP/loxP mice
were crossed to generate ApcloxP/loxPPtenloxP/loxP mice.
At 8–10 weeks of age, AdCre was injected into the right
ovarian bursa of 50 ApcloxP/loxPPtenloxP/loxP females. A
subset of mice (n = 29) was followed to assess the natural
history of tumor progression. Tumors (hereafter referred to
as APC/PTEN tumors) developed in the AdCre injected
ovary with 100% penetrance (Figure 3A). Tumors were
grossly apparent within 6 weeks of AdCre injection
(Figure 3B), and animals died or were euthanized perguidelines for the humane treatment of animals within 19
weeks after AdCre injection (range 7–19 weeks, average
11.5 weeks). The mouse tumors pursued a course similar
to untreated human ovarian carcinoma, with 76% of ani-
mals developing hemorrhagic ascites (Figure 3C), and
a smaller subset (21%) developing overt peritoneal dis-
semination. Once established, tumor volume doubled
roughly every 3 weeks (Figure 3D). A survival curve for
the cohort of 29 AdCre-injected ApcloxP/loxPPtenloxP/loxP
mice is provided in Figure 3E. To date, we have not iden-
tified ovarian tumor formation in any of 33 wild-type, 61
ApcloxP/loxP, or 63 PtenloxP/loxP mice following ovarian bur-
sal injection with AdCre (surveillance period ranging from
30–42 weeks).
The APC/PTEN tumors showed morphological simi-
larity to human OEAs, with formation of distinct glands
and occasional foci of squamous differentiation (Figures
4A–4D). As expected for tumors with epithelial differentia-
tion, immunohistochemical staining for cytokeratins 8 and
19 was strongly positive in the tumor cells (Figures 4E and
4F). In 6 of 29 animals, peritoneal dissemination of tumor
wasmanifested by tumor implants on the liver serosa (Fig-
ures 4G and 4H). Perivascular tumor within the liver paren-
chyma of these mice was occasionally observed. Also, as
anticipated, the murine tumors that developed in the
setting of Apc and Pten inactivation showed nuclear ac-
cumulation of b-catenin protein but lacked detectable
expression of PTEN (Figures 5A and 5B). Similar to the
tumors developing in the setting of K-RAS activation and
PTEN inactivation described by Dinulescu et al. (hereafter
referred to as K-RASmut/PTEN tumors) the APC/PTEN
tumors showed increased pS6 staining, indicative of acti-
vated signaling through AKT (Figure 5C). The APC/
PTEN tumors also showed significant areas of less dif-
ferentiated mesenchymal-appearing cells with vague
spindle-cell morphology (Figures 5D and 5E). These areas
are negative for cytokeratins (Figure 5F) and showed loss
of E-cadherin immunoreactivity (Figure 5G) compared
to portions of the tumor with glandular differentiation,
suggesting epithelial-mesenchymal transition. ActivatedCancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc. 325
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Mouse Model of Ovarian Endometrioid AdenocarcinomaFigure 3. Inactivation of Apc and Pten in the Ovarian Surface Epithelium Induces Ovarian Carcinomas
(A) Female genital tract from ApcloxP/loxPPtenloxP/loxP mouse 11 weeks after ovarian bursal AdCre injection. The right (injected) ovary shows a large,
hemorrhagic tumor mass.
(B) Female genital tract from ApcloxP/loxPPtenloxP/loxP 6 weeks after AdCre injection. Note the small tumor present in the right (injected) ovary.
(C) Representative mouse with carcinoma showing massive abdominal distension by hemorrhagic ascites.
(D) Tumor growth curve shows that tumor size doubles roughly every 3 weeks; bars indicate mean ± SD.
(E) Survival of ApcloxP/loxPPtenloxP/loxP mice (red, n = 29) following AdCre injection versus wild-type control mice (black, n = 33).Wnt/b-cat and PI3K/Pten signaling have both been impli-
cated in epithelial-mesenchymal transition, a process
thought to contribute to increased invasiveness and met-
astatic potential during tumor progression (reviewed by
Larue and Bellacosa, 2005) (Brabletz et al., 2005). The
mesenchymal-appearing areas do not likely represent
malignant transformation of gonadal stroma (such as
granulosa cell tumor), since they failed to express inhibin,
a marker of gonadal stromal differentiation (Figure 4H).
Moreover, we have examined several ROSA26 reporter
mice after ovarian bursal injection of AdCre and never ob-
served b-galactosidase activity in ovarian stromal or other
nonepithelial cells.
Comparison of Gene Expression in the APC/PTEN
Murine Tumors to Human Ovarian Carcinomas
Shows Greatest Similarity of the Mouse Tumors
to Human OEAs with Deregulation of Wnt/b-catenin
and/or PI3K/Pten Signaling
As described above, we used Affymetrix U133A oligonu-
cleotide arrays to generate comprehensive gene expres-
sion data from 99 primary human ovarian carcinomas326 Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc.including all four of the major histologic types. We also
profiled gene expression in four human ovaries inciden-
tally removed from premenopausal women. Seven snap-
frozen mouse APC/PTEN ovarian tumors 9 weeks after
AdCre injection and eight contralateral (normal unin-
fected)/control ovaries from ApcloxP/loxPPtenloxP/loxP mice
were collected for use in gene expression-profiling exper-
iments. mRNA was extracted from mouse tumor and
whole normal ovary samples using the same methods
we successfully employed previously for human tumor tis-
sues. In order to obtain sufficient mRNA from the small
normal mouse ovary specimens, normal ovary samples
were combined into four groups of two samples each.
We opted to compare gene expression in the tumors to
that in whole normal ovary rather than ovarian surface ep-
ithelium because it is not possible to obtain sufficient
quantities of nonneoplastic OSE for expression profiling
without prior expansion of the cell population in culture,
or alternatively, linear amplification of RNA isolated by la-
ser capture microdissection before preparation of labeled
cRNA. The normal mouse and human ovary samples
serve as a common reference point for comparison of
Cancer Cell
Mouse Model of Ovarian Endometrioid Adenocarcinomagene expression in tumors from mouse and human, re-
spectively. Having a reference point with which to com-
pare the tumor gene expression is essential because com-
parable hybridization of mouse and human cRNAs to
probe sets representing homologous genes in the mouse
and human cannot be assumed. The values obtained for
each gene for these common control samples serve to
calibrate the assays on the two arrays, compensating for
possible differences in the affinities of the probes to their
target sequences or the efficiency with which labeled
cDNA is produced from the initial RNA samples.
Principal component analysis determined that the
mouse tumor and normal ovary samples are easily sepa-
rable based on global gene expression profile (data not
Figure 4. Murine Tumors Arising in ApcloxP/loxPPtenloxP/loxP
Animals Resemble Human OEAs with Respect to Morphol-
ogy, Immunophenotype, and Biological Behavior
(A) Human OEA showing distinct gland formation and focal squamous
differentiation (arrows). (B) Human OEA showing prominent squamous
differentiation with focal keratinization (arrows). Mouse OEA-like tumor
showing gland formation (C) and focal squamous differentiation (D)
(arrows). Immunostains for cytokeratin 8 (E) (inset shows normal endo-
metrium as positive control) and cytokeratin 19 (F) (inset shows normal
ovarian surface epithelium as positive control) confirm epithelial differ-
entiation of the tumor cells. A subset of animals showed dissemination
of tumor on peritoneal surfaces, especially the liver serosa (G and H).
Scale bars, 100 mm in (A)–(C) and (E)–(H), 40 mm in (D).shown). A similar analysis was performed for the human
normal ovaries and ovarian carcinomas profiled on Affy-
metrix U133A arrays. Comparison of the seven mouse tu-
mors and four normal pooled ovary samples identified
1088 probe sets with p < 0.001 and a minimum of 5-fold
differences between tumor and normal (608 increased in
tumors; 480 decreased). In order to estimate how many
of these differences are likely false positives, we used
the same selection criteria on 1000 data sets in which
the sample labels were randomly permuted and obtained
only 6.6 probe sets on average. Consequently, the esti-
mated false discovery rate is excellent, at 0.61%.
The 1088 probe sets selected from the mouse data rep-
resent 774 distinct genes, 486 of which have orthologs
represented on the human arrays. We correlated the aver-
age tumor-normal differences in log expression for these
486 mouse genes with the corresponding human genes’
tumor-normal differences for each of the 99 human tumor
samples. All correlations were positive (Table S2), ranging
from 0.21 to 0.37, with the exception of a mucinous tumor
with a correlation of 0.16. Ranking correlations from all
four groups of human tumors gave average ranks of
61.1, 53.8, 42.6, and 30.1 for endometrioid, mucinous, se-
rous, and clear-cell tumors, respectively. Endometrioid
had higher-ranking correlations than clear cell (p =
0.0066, rank-sum test) and serous tumors (p = 0.0041);
however, the difference between endometrioid and mu-
cinous tumors was not significant (p = 0.48).
Notably, of the 99 human ovarian tumors with associ-
ated microarray-based expression data, 10 of the 13 hu-
man ovarian tumors most highly correlated to the mouse
tumors’ data were endometrioid, including the top six (Fig-
ure 6A and Table S2). Four of these six OEAs contained
mutant b-catenin (OE-13T, -18T, -48T, and -55T), three
of which also had mutations of PTEN (OE-13T, -48T, and
-55T) and/or PIK3CA (OE-55T). These mutations, which
deregulate the Wnt/b-cat and PI3K/Pten signaling path-
ways, likely cause a subset of the human tumors to be
more correlated to the mouse tumors. Other highly
correlated human tumors may also harbor mutations
that deregulate Wnt/b-cat and PI3K/Pten signaling, al-
though we have not yet collected these mutational data
on the nonendometrioid cancers. The significantly higher
correlations of OEAs as a group is most probably due to
the greater frequency of tumors with such mutations in
this group compared to the other histological types of
ovarian carcinomas. We then compared the correlations
of several subsets of endometrioid tumors defined by
CTNNB1/APC mutation status or b-catenin immuno-
histochemical staining pattern using two-sided rank-sum
tests, the results of which are shown in Figure 6B. Tumors
with CTNNB1 or APC mutations had higher correlations
to the mouse tumor profile (p = 0.0044), as did tumors
exhibiting nuclear accumulation of b-catenin (p = 0.0011).
Low-stage (1 and 2) tumors had higher correlations than
higher-stage (3 and 4) tumors (p = 0.0003).
We conclude that our mouse model of ovarian cancer,
based on conditional deletion of Apc and Pten, shows
morphological features, biological behavior, and geneCancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc. 327
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Mouse Model of Ovarian Endometrioid AdenocarcinomaFigure 5. Murine APC/PTEN OEA-Like
Tumors Show Evidence of Deregulated
Wnt/b-cat and PI3K/Pten Signaling and
Changes Suggestive of Epithelial-Mes-
enchymal Transition
Representative mouse tumor shows nuclear
accumulation of b-catenin protein (A), loss of
PTEN expression (B) (inset: normal mouse en-
dometrium as positive control), and increased
expression of pS6 (C). (D) Areas of tumor with
spindle cell morphology (left) admixed with
recognizable glandular elements (right) were
often observed. These spindle cell areas
(higher magnification in [E]) showed loss of
cytokeratin 8 (F) and E-cadherin (G) expres-
sion, suggestive of epithelial-mesenchymal
transition. An immunostain for inhibin (H),
a marker of gonadal stromal differentiation, is
negative in the tumor cells (note inhibin-posi-
tive follicular cells in upper left). Scale bars,
100 mm in (A)–(D) and (F)–(H), 40 mm in (E).expression profiles similar to human cancers with the
same signaling pathway defects.
DISCUSSION
Ovarian carcinomas are a morphologically heterogeneous
group of tumors that can be divided into four major types
based on their features when viewed by light microscopy.
A number of characteristic genetic alterations have been
identified in ovarian carcinomas, though the frequency328 Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc.with which a given gene is mutated varies substantially
among the different subtypes (Bell, 2005). As our under-
standing of the molecular defects in ovarian cancer be-
comes more complete, characterization of the specific
mutations in each individual tumor will likely bemore infor-
mative than knowledge of the average behavior of the his-
tological type to which the tumor belongs. Clearly, such
specific information would aid in the design and use of ef-
fective drugs that target the particular molecular defects
of the cancer cells. OEAs are the second most commonFigure 6. Gene Expression Profiling of
Murine OEA-Like Tumors and Human
Ovarian Carcinomas
(A) Correlation of differences from normal for
genes altered in APC/PTEN murine tumors
compared to groups of human ovarian carcino-
mas (OC, clear cell; OE, endometrioid; OM,
mucinous; OS, serous).
(B) Correlations of mouse tumors to several
subsets of human OEAs defined by CTNNB1/
APC mutation status, b-catenin staining pat-
tern, and stage (p values from two-sided
rank-sum tests).
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Mouse Model of Ovarian Endometrioid Adenocarcinomatype of ovarian carcinoma, after serous carcinomas. We
examined a large number of human OEAs to search for
concomitant mutational defects in selected signaling
pathways. We found a statistically significant correlation
between defects in Wnt/b-cat and PI3K/Pten signaling.
Indeed, two-thirds of OEAs with PTEN mutations also
have Wnt/b-cat pathway defects. The OEAs with muta-
tions predicted to deregulate Wnt/b-cat and/or PI3K/
Pten signaling are typically low grade and distinguishable
from the high-grade OEAs, which have a high prevalence
of p53 mutations. Based on co-occurrence of these
pathway defects in a subset of primary human OEAs,
we investigated whether these signal transduction cas-
cades work together to promote transformation in an in
vivo model of ovarian cancer. The murine tumors that
arise in the setting of Apc and Pten inactivation have
similar histological features and gene expression profiles
to their human OEA counterparts with comparable Wnt/
b-cat and PI3K/Pten signaling pathway defects. All
Apcloxp/loxpPtenloxP/loxP mice developed tumors in the
ovary injected with AdCre but not in the contralateral,
uninjected ovary. Disease progression in these mice
following AdCre injection is rapid and similar to that
observed in women with untreated ovarian cancer, with
frequent development of hemorrhagic ascites and perito-
neal dissemination of tumor.
Although mice with ovarian epithelial-specific activation
of K-RAS and inactivation of PTEN also develop tumors
histologically resembling human OEAs (Dinulescu et al.,
2005), our data indicate that activating K-RAS and inacti-
vating PTEN mutations rarely if ever coexist in human
OEAs. As such, the APC/PTENmurine tumorsmay offer
a useful complement to the K-RASmut/PTEN tumors for
studying the biology of OEAs and for preclinical testing
of molecularly targeted therapeutics likely to be effective
in treating human OEAs. Notably, however, the tumors
arising in the ApcloxP/loxPPtenloxP/loxP mice are not accom-
panied by endometriosis. Dinulescu and colleagues found
that endometriosis-like lesions often developed after
ovarian bursal injection of AdCre allowing activation of
an oncogenic K-ras allele. This is an intriguing observa-
tion, since the association of endometriosis with both en-
dometrioid and clear-cell ovarian adenocarcinomas has
long been recognized (Fukunaga et al., 1997; Erzen
et al., 2001). Despite this association, data supporting en-
dometriosis as an obligate precursor of OEA are lacking,
and the role of oncogenic K-ras in the pathogenesis of en-
dometriosis remains uncertain. Indeed, several studies
failed to identify K-RASmutations in human endometriotic
lesions (Vercellini et al., 1994; Amemiya et al., 2004;
Otsuka et al., 2004). Dinulescu and colleagues proposed
that alternative mechanisms of RAS pathway activation
may be involved in the development of endometriosis. In
any event, Wnt/b-cat signaling pathway activation does
not appear to be directly related to endometriosis, at least
in our mouse model. We have not identified b-catenin mu-
tations in human endometriotic lesions in the absence of
endometrioid adenocarcinoma (Y.Z., R.W., and K.R.C.,
unpublished data).The mechanism for synergistic effects of activating the
PI3K/Pten andWnt/b-cat signaling pathways in this model
is unclear at this point. Akt has a number of substrates,
one of which is GSK3b. However, Akt’s ability to nega-
tively regulate GSK3b’s activity on b-catenin remains un-
certain (Yuan et al., 1999), and mutant b-catenin alleles
are resistant to regulation by GSK3b. Some studies sug-
gest the GSK3b pools associated with the Wnt and
PI3K/Pten pathways are distinct, while others suggest
these pools are not mutually exclusive and may interact
to mediate effects of upstream growth factor activators
(reviewed by Mulholland et al., 2006). Recently, Wnt has
been shown to activate mTOR (a downstream effector of
activated Akt) via inhibition of GSK3b, but without involv-
ing b-catenin-dependent transcription (Inoki et al., 2006).
Hence, while the two pathways intersect, themechanisms
for their cooperation in cancer pathogenesis are not
obvious.
As indicated above, either activation of K-RAS or dereg-
ulation of b-catenin can cooperate with AKT activation in
mouse models of ovarian carcinoma. Notably, activation
of Akt is one of the most common occurrences in human
cancer. One model postulated to explain this is that acti-
vated Akt upregulates glycolysis, which is thought to be
required to support the high rate of cancer cell prolifera-
tion (Bui and Thompson, 2006; Thompson and Thompson,
2004). Several studies have found that deregulated PI3K/
Pten signaling is a major determinant of cell growth and
survival in many cancer types, and a number of small mol-
ecules targeting the upstream and downstream compo-
nents of this pathway have been developed (reviewed by
Powis et al., 2006 and Granville et al., 2006). Given the im-
portance of PI3K/Pten signaling in regulating the growth
properties of normal cells, as well as the complexity of
its regulation, it may be difficult to identify efficacious an-
ticancer drugs with acceptably low toxicity. However, re-
cent work showing that inhibition of mTOR by treatment
with rapamycin can inhibit the growth of Pten-deficient
leukemia cells while restoring hematopoietic stem cell
growth (Yilmaz et al., 2006) suggests that such agents
can be identified. Whether rapamycin has similar effects
on the APC/PTENmurine tumors is under investigation.
Animal models that can be used to test PI3K/Pten path-
way inhibitors, alone and in combination, will likely prove
particularly useful in the development of new therapeutics.
Although development of Wnt signaling pathway inhib-
itors as cancer therapeutics is not as far advanced as that
for PI3K signaling, some small molecules antagonizing the
interaction of b-catenin with key nuclear proteins have
been identified (Lepourcelet et al., 2004; Emami et al.,
2004; Janssens et al., 2006). The observation that canon-
ical Wnt signaling also upregulates the activity of mTOR
(Inoki et al., 2006) provides further impetus for testing ef-
fects of rapamycin and its analogs in this model system.
The APC/PTEN murine ovarian tumors described here
have similar genetic defects, morphology, and clinical be-
havior to their human OEA counterparts, and this model of
OEA should prove useful in evaluating both chemopreven-
tive and chemotherapeutic strategies for ovarian cancer.Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc. 329
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Human Tumor Samples
Seventy-two snap-frozenOEA sampleswere analyzed formutations of
CTNNB1,K-RAS,PTEN,PIK3CA, and TP53: 60 sampleswere from the
Cooperative Human Tissue Network/Gynecologic Oncology Group
Tissue Bank, 6 were from Johns Hopkins Hospital, 5 were from Kuma-
moto University Hospital, and 1 was from the University of Michigan
Health System. OEAs were classified as well differentiated (grade 1,
n = 18), moderately differentiated (grade 2, n = 26), or poorly differen-
tiated (grade 3, n = 28) using FIGO criteria. FIGO criteria were also used
to assign tumor stage (stage 1, n = 29; stage 2, n = 15; stages 3 and 4,
n = 28). Primary tumor tissues were manually dissected with micro-
scope guidance to ensure that each tumor sample contained a mini-
mum of 70% tumor cells. Genomic DNA and RNA were isolated
from pooled frozen tissue sections using standard techniques as we
have described previously (Wu et al., 2001). Mutational analyses of
CTNNB1, K-RAS, PTEN, PIK3CA, and p53 were performed on all 72
OEAs using published and custom primer sequences (unpublished
primer sequences provided upon request) (Wu et al., 2001; Oda
et al., 2005). A small subset of OEAs with nuclear accumulation of
b-catenin protein but lacking CTNNB1 mutations were evaluated for
APC mutations in a previously reported study (Wu et al., 2001). A set
of 99 snap-frozen primary ovarian carcinomas were used for expres-
sion profiling, including 41 serous, 37 endometrioid, 13 mucinous,
and 8 clear cell carcinomas. The 37 OEAs used for the expression pro-
filing analysis were included in the mutational analysis of 72 OEAs de-
scribed above. Analysis of tissues from human subjects was approved
by the University of Michigan’s Institutional Review Board (IRBMED
protocols 1999-0428 and 2001-0568).
Immunohistochemical Staining of Human Tumors
Formalin-fixed, paraffin-embedded OEA tissues were immunohisto-
chemically stained for b-catenin, Pten, pS6 ribosomal protein, and
p53 using standard techniques. Methods for immunohistochemical
analysis of b-catenin have been previously described (Zhai et al.,
2002). Sections were immunostained using mouse monoclonal anti-
Pten antibody (1:400, Clone 6H2.1, Cascade Biosciences, Winchester,
MA), mouse monoclonal anti-p53 antibody (1:500, clone DO-7, Invitro-
gen, San Diego, CA), or rabbit polyclonal anti-pS6 ribosomal protein
(1:500, clone 91B2, Cell Signaling Technology, Danvers, MA). Anti-
gen-antibody complexes were detected with the avidin-biotin peroxi-
dase method using NovaRed (Pten) or 3,30-diaminobenzidine as
a chromogenic substrate (b-catenin, pS6, p53) (Vectastain ABC kit;
Vector Laboratories, Burlingame, CA). Immunostaining for Pten and
nuclear b-catenin was scored on a three-tiered scale for intensity
(, absent; +, retained; ++, strongly retained) in the epithelial portions
of tumor sections compared to the stromal components. Immunos-
taining for nuclear accumulation of p53 was scored as negative
(absent or weak/focal) or positive (strong and diffuse).
Mouse Strains
ApcloxP/loxP mice and PtenloxP/loxP mice have been previously
described in detail (Shibata et al., 1997; Suzuki et al., 2001).
ApcloxP/loxPPtenloxP/loxP mice were generated by crossbreeding
ApcloxP/loxP with PtenloxP/loxP mice. The genotype of each strain was
confirmed by PCR using tail biopsy DNA and primer sequences
described previously (Backman et al., 2001; Shibata et al., 1997).
Gt(ROSA)26Sor reporter mice (R26R) were purchased from Jackson
Laboratories (Bar Harbor, ME) (Soriano, 1999). All animal procedures
were approved by the University of Michigan’s Committee on Use
and Care of Animals (UCUCA, protocol #8742).
Ovarian Tumor Development after Intrabursal Injection
of Adenovirus Expressing Cre Recombinase
Replication-incompetent recombinant adenovirus expressing Cre re-
combinase under the control of the CMV promoter (AdCre) (Anton
and Graham, 1995) was obtained from University of Michigan’s Vector330 Cancer Cell 11, 321–333, April 2007 ª2007 Elsevier Inc.Core. Plaque-forming units (pfu; 5 3 107) of AdCre with 0.1% Evans
blue (Sigma-Aldrich Inc., St. Louis, MO) in a total volume of 5 ml was
injected into the right ovarian bursal cavity of 56- to 70-day-old female
mice. A 32-gauge needle was introduced into the oviduct near the
infundibulum and into the ovarian bursa as described previously
(Flesken-Nikitin et al., 2003; Dinulescu et al., 2005). The left ovarian
bursa was not injected and served as a normal control. A total of 80
ApcloxP/loxP, 70 PtenloxP/loxP, 50 ApcloxP/loxP/PtenloxP/loxP, and 40 C57BL6
wild-type mice underwent intrabursal injection of AdCre. Localization
of Cre expression to the ovarian surface epithelium after intrabursal
injection of AdCre was evaluated in R26R reporter mice. Seventy-
two hours after a single intrabursal injection of AdCre, reporter mice
were euthanized and the female genital tract, liver, kidneys, spleen,
digestive tract, lungs, and heart were harvested and fixed in 4% para-
formaldehyde for 20 min, then stained in X-gal (Invitrogen) solution for
2 hr at 37C. After staining, tissues were postfixed in 4% parafor-
maldehyde, dehydrated in 30% sucrose, and embedded in OCT
compound. Frozen sections were counterstained with nuclear fast
red (Sigma-Aldrich Inc.). Following AdCre injection, all ApcloxP/loxP,
PtenloxP/loxP, ApcloxP/loxP/PtenloxP/loxP, and wild-type mice were moni-
tored at least twice weekly until palpable tumors were detected, and
daily after tumor formation was evident. Twenty-nine mice died spon-
taneously or were euthanized by CO2 asphyxiation when clinical signs
of morbidity associated with tumor burden were identified, in com-
pliance with the institutional guidelines. A subset of ApcloxP/loxP/
PtenloxP/loxP mice were euthanized 6 weeks after AdCre injection to
determine if ovarian tumors were present at this time point. Another
subset of ApcloxP/loxP/PtenloxP/loxP mice were euthanized 9 weeks after
injection to obtain tumors for gene expression profiling studies.
Genomic DNA from tumors was prepared as previously described
(Wu et al., 2001). PCR was performed using mouse tumor and normal
DNA to validate Cre-mediated recombination of Apc and Pten alleles.
Mouse Tissue Histopathology
All micewere examined at necropsy for gross organ abnormalities. The
genital system, liver, lungs, spleen, kidney, brain, and digestive tract
were collected, fixed in 10% (v/v) buffered formalin, and embedded
in paraffin for histopathological evaluation. Histopathological evalua-
tion of tumor and other tissueswas performed by a surgical pathologist
with expertise in ovarian cancer diagnosis (K.R.C.).
Immunohistochemical Staining of Mouse Tumor Tissues
Immunohistochemical staining was performed on formalin-fixed, par-
affin-embedded tissue sections using standard methods. For mouse
primary monoclonal antibodies (anti-b-catenin, 1:500, Transduction
Laboratories, Lexington, KY; and anti-inhibin, 1:50, Serotac Ltd,
Oxford, UK), the Mouse on Mouse kit (M.O.M., Vector laboratories)
was used to reduce nonspecific staining per the manufacturer’s in-
structions. Rat monoclonal antibodies to CK8 (TROMAI, 1:10) and
CK19 (TROMAIII, 1:10) were obtained from the Developmental Studies
Hybridoma Bank (The University of Iowa, Iowa City, IA). Other anti-
bodies employed included anti-E-cadherin (1:200, clone ECCD-2,
Zymed, South San Francisco, CA), anti-PTEN (1:100, clone 138G6,
Cell Signaling Technology), anti-pS6 (1:100, clone 91B2, Cell Signaling
Technology), and biotinylated rabbit anti-rat IgG (BA-4001, Vector
Laboratories).
Gene Expression Profiling
Frozen mouse tumor tissues were manually microdissected before
RNA extraction to ensure that each tumor sample contained at least
90% neoplastic cells in tumor samples. Matched normal ovaries
were used for controls. RNA isolation and cRNA synthesis were per-
formed as previously described (Schwartz et al., 2002). cRNAs were
hybridized to GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix,
Santa Clara, CA). The arrays were scanned using Affymetrix Scanner
3000. Image analysis was performed with GeneChip software (Affyme-
trix). Human tumor and ovary samples were hybridized to U133A
Arrays (Affymetrix).
Cancer Cell
Mouse Model of Ovarian Endometrioid AdenocarcinomaGene Expression Data Analysis
Array hybridization, scanning, and image analysis, using Human Ge-
nome U133A arrays with 22283 probe sets, were performed according
to the manufacturer’s protocols (Affymetrix, Santa Clara, CA). Probe-
set intensities were obtained and normalized as previously described,
using publicly available software (Giordano et al., 2001). Mouse sam-
ples and arrays were processed using methods identical to those
used for human tissues, except that Mouse430_2 arrays with 45,101
probe sets were used, and the probe-set intensities were scaled to
give an average of 1000 rather than 1500 units. Data were log trans-
formed using Y = log(max(x + 50,0) + 50) for both the mouse and hu-
man data sets, and all subsequent analysis used only the transformed
data. Fold changes between groups of samples were based on the av-
erages of the transformed data. The array data are available from
NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.
gov/geo/) using series accession numbers GSE6008 (human arrays)
and GSE5987 (mouse arrays). Annotations indicating the gene repre-
sented by each probe set as of December 19, 2005, were obtained
from Affymetrix web sites for both human and mouse arrays. Mouse
genes were joined to human homologs using downloads of Homolo-
gene from NCBI web sites, obtained January 12, 2006.
Supplemental Data
The Supplemental Data include two supplemental tables and can be
found with this article online at http://www.cancercell.org/cgi/
content/full/11/4/321/DC1/.
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